NewAmsterdam Pharma Co NV (FRA:KH6) Change In Receivables : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Change In Receivables?

NewAmsterdam Pharma Co NV's change in receivables for the quarter that ended in Dec. 2023 was €0.00 Mil. It means NewAmsterdam Pharma Co NV's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

NewAmsterdam Pharma Co NV's change in receivables for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means NewAmsterdam Pharma Co NV's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

NewAmsterdam Pharma Co NV's Accounts Receivable for the quarter that ended in Dec. 2023 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. NewAmsterdam Pharma Co NV's Days Sales Outstanding for the six months ended in Dec. 2023 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. NewAmsterdam Pharma Co NV's liquidation value for the six months ended in Dec. 2023 was €258.36 Mil.

NewAmsterdam Pharma Co NV Change In Receivables Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV Change In Receivables Chart

NewAmsterdam Pharma Co NV Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Receivables

NewAmsterdam Pharma Co NV Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial			-	-113.64	-	-	-

NewAmsterdam Pharma Co NV Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

NewAmsterdam Pharma Co NV (FRA:KH6) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

NewAmsterdam Pharma Co NV's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	3.392	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, NewAmsterdam Pharma Co NV's accounts receivable are only considered to be worth 75% of book value:

NewAmsterdam Pharma Co NV's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	312.193	-	53.832	+	0.75 * 0	+	0.5 * 0
=	258.36

NewAmsterdam Pharma Co NV Change In Receivables Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

NewAmsterdam Pharma Co NV (FRA:KH6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (FRA:KH6) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

NAMS:USA KH6:Germany

Address

Gooimeer 2-35, Naarden, NH, NLD, 1411 DC

Website

https://www.newamsterdampharma.com

NewAmsterdam Pharma Co NV is a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases and Alzheimer's disease.

NewAmsterdam Pharma Co NV (FRA:KH6) Headlines

No Headlines